(Reuters) -Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion. EsoBiotec's ...

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

In the study cohort, 2,310 patients died during a median follow-up of 6.3 years, and prostate cancer accounted for 454 (19.7% ...

People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...

EsoBiotec announced it has entered into a definitive agreement to be acquired by AstraZeneca (AZN). The EsoBiotec Engineered NanoBody ...

AstraZeneca has struck a deal to acquire biotechnology EsoBiotec for up to $1bn, as the London-listed pharmaceuticals group ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca ( NASDAQ: AZN) for up to $1 billion, on a ...

CAMBRIDGE, UK] Drugmaker AstraZeneca said on Monday (Mar 17) it will buy biotechnology firm EsoBiotec for up to US$1 billion.

AstraZeneca will acquire EsoBiotec for a total consideration of up to $1billion, on a cash and debt free basis. This will ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...